person · Reporting owner
Keswani Sanjay Chandru
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | EVP & Chief Medical Officer | February 11, 2022 | February 15, 2022 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Medical Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date February 11, 2022 · Filed February 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
After 2022-02-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-11 · Grant · Acquired 12,500 · Balance 12,500 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 11 of each year, with the first 1/3rd vesting on February 11, 2023. F2: Includes 12,500 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.94 · Expires 2032-02-11 | Direct | 100,000 |
Reported balance
After 2022-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-11 · Grant · Acquired 100,000 · Balance 100,000 F3: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 11 of each year, with the first 1/3rd vesting on February 11, 2023.
F2: Includes 12,500 RSUs.
F3: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,281 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 3,914 · Balance 5,393 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,112 · Balance 3,281 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,112 | $156.22 | $329,936.64 |
DisclosureSEC source: 0001818524-26-000006 · wk-form4_1789506353.xml · nonDerivative · entry 2 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,281 F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 3,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001818524-26-000006 · wk-form4_1789506353.xml · nonDerivative · entry 1 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,393 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 21:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 3,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001818524-26-000004 · wk-form4_1780610055.xml · derivative · entry 3 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,634 Underlying: Common Stock · 3,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on June 2, 2025. In accordance with the terms of the RSU, the award vested as to 3,212 shares on June 2, 2026, and will vest as to 3,212 shares on June 2, 2027, 3,211 shares on June 2, 2028, and 3,211 shares on June 2, 2029, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on June 2, 2025. In accordance with the terms of the RSU, the award vested as to 3,212 shares on June 2, 2026, and will vest as to 3,212 shares on June 2, 2027, 3,211 shares on June 2, 2028, and 3,211 shares on June 2, 2029, subject to the terms and conditions of the award. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 21:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,733 | $154.84 | $268,337.72 |
DisclosureSEC source: 0001818524-26-000004 · wk-form4_1780610055.xml · nonDerivative · entry 2 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 21:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001818524-26-000004 · wk-form4_1780610055.xml · nonDerivative · entry 1 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001818524-26-000002 · wk-form4_1771368237.xml · derivative · entry 2 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,285 Underlying: Common Stock · 6,285 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 35,827 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001818524-26-000002 · wk-form4_1771368237.xml · derivative · entry 1 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,827 Underlying: Common Stock · 35,827 shares Expires 2036-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 70,101 | $0.00 Strike: $124.56 | $0.00 |
DisclosureSEC source: 0000914475-25-000146 · wk-form4_1749073054.xml · derivative · entry 2 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,101 Underlying: Common Stock · 70,101 shares Expires 2035-06-02 F3 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on June 2, 2026 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,846 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000146 · wk-form4_1749073054.xml · derivative · entry 1 Keswani Sanjay Chandru · CIK 0001818524 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,846 Underlying: Common Stock · 12,846 shares Expires not disclosed F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. F2 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of June 2, 2026, June 2, 2027, June 2, 2028, and June 2, 2029. F2 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of June 2, 2026, June 2, 2027, June 2, 2028, and June 2, 2029. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.94 | $0.00 |
DisclosureSEC source: 0001567619-22-004613 · doc1.xml · derivative · entry 2 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-11 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004613 · doc1.xml · nonDerivative · entry 1 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 11 of each year, with the first 1/3rd vesting on February 11, 2023. F2 · balance_after: Includes 12,500 RSUs. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,995 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001567619-21-007084 · doc1.xml · derivative · entry 3 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,956 Underlying: Common Stock · 3,995 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | SaleCommon Stock | 3,995 | $30.17 | $120,511.97 |
DisclosureSEC source: 0001567619-21-007084 · doc1.xml · nonDerivative · entry 2 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $30.00 to $30.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | Exercise / conversionCommon Stock | 3,995 | $7.49 | $29,916.56 |
DisclosureSEC source: 0001567619-21-007084 · doc1.xml · nonDerivative · entry 1 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:08 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $30.07 | $0.00 |
DisclosureSEC source: 0001567619-21-005223 · doc1.xml · derivative · entry 1 Keswani Sanjay · CIK 0001818524 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 25, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.